Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controlsTravis T. Sims, Ann H. Klopp, Lauren E. Colbert et al.|Gynecologic Oncology|2019Cited by 110
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancerJeffrey How, Amir A. Jazaeri, Shrina Patel et al.|Gynecologic Oncology|2021Cited by 56
A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancersMolly B. El Alam, Lauren E. Colbert, Lilie L. Lin et al.|PLoS ONE|2021Cited by 38
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trialJeffrey How, Aung Naing, Amir A. Jazaeri et al.|Investigational New Drugs|2021Cited by 25
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational OpportunitiesAnne Knisely, Amir A. Jazaeri, Yibo Dai et al.|Clinical Cancer Research|2025Cited by 10